Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SEINRLF 56 14-Day RSI is 47.01 as of Jul. 19, 2026. GuruFocus rates INRLF with a GF Score™ of 56/100 and a GF Value™ of $2.68 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,425 Biotechnology companies, Valneva SE ranks better than 76.98% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-19), Valneva SE's 14-Day RSI is 47.01.
The industry rank for Valneva SE's 14-Day RSI or its related term are showing as below:
INRLF's 14-Day RSI is ranked better than 76.98% of 1425
companies
in the Biotechnology industry
Industry Median: 45.58
vs INRLF: 47.01
Valneva SE (OTCPK:INRLF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Valneva SE 14-Day RSI Related Terms
INRLF vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Valneva SE's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Valneva SE's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (INRLF) has a 14-Day RSI of 47.01 as of Jul. 19, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #328 out of 1425 companies in the Biotechnology industry, placing it in the top 23%.
Is Valneva SE's 14-Day RSI too high?
Valneva SE's current 14-Day RSI is 47.01. The Biotechnology industry median 14-Day RSI is 45.58. Valneva SE's value of 47.01 is 3.1% above this industry median. Based on the distribution chart, Valneva SE ranks #328 out of 1425 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valneva SE has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #328 out of 1425 companies for 14-Day RSI. This places Valneva SE in the top 23% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 45.58. Valneva SE's value of 47.01 is 3.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.58, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current 14-Day RSI of 47.01 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current 14-Day RSI is 47.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.68, compared to a current price of $2.62 — trading 2.2% below its estimated fair value. The current 14-Day RSI is 47.01 and 3.1% above the Biotechnology industry median of 45.58. Valneva SE's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Valneva SE (INRLF), the current 14-Day RSI is 47.01 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 2.2% below its estimated GF Value™ of $2.68.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for INRLF:
14-Day RSI: 47.01
GF Value™: $2.68 vs. price of $2.62 (2.2% below fair value)
Industry Position: 3.1% above the Biotechnology median (#328 of 1425)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
56GF Score
Get the complete analysis for INRLF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
